Amicus Therapeutics Inc

Amicus Therapeutics — Q2 2023 Earnings Presentation

24 slides from Amicus Therapeutics's earnings presentation, Aug 8, 2023

  1. Slide 1: 2Q23 Results Conference Call & Webcast

    AT T H E F O R E F RO N T O F THERAPIES FOR RARE DISEASES 2Q23 Results Conference Call & Webcast August 8, 2023

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and c

  3. Slide 3: A Rare Company

    A Rare Company Patient-dedicated, rare disease biotechnology company with sustained double-digit revenue growth, a global commercial infrastructure, and late-stage development capabilities World-class Gene Therapy Clinical Platform Non-GAAP GLOBAL Development PROFITABILITY COMMERCIAL Capabilities Le

  4. Slide 4: Strategic Priorities

    2023 1 Sustain double-digit Galafold revenue growth of 14-18% at CER1 Strategic Priorities 2 Secure FDA, EMA, and MHRA approvals for AT-GAA 3 Initiate successful global launches of AT-GAA Advance best-in-class, next-generation Fabry and Pompe pipeline 4 programs and capabilities 5 Maintain strong fi

  5. Slide 5: Galafold (migalastat) Continued Growth

    Galafold® (migalastat) Continued Growth Building a leadership position in the treatment of Fabry disease 5

  6. Slide 6: 2023 Galafold Success (as of June 30, 2023)

    2023 Galafold Success (as of June 30, 2023) Building on Galafold’s success and leveraging leadership position to drive continued growth Galafold is the first and only approved oral treatment option with a unique mechanism of action for Fabry patients with amenable variants 94.3M $ 2Q23 Galafold 60%

  7. Slide 7: Galafold Performance

    Galafold Performance Raising FY23 revenue growth guidance to 14% to 18% at CER $375M - $388M2 $329M1 $306M  Global mix of switch (~45%) and previously $261M Q4 untreated patients (~55%)3 $88M Q3  Compliance and adherence over 90%+ $182M $82M Q2  Expect non-linear quarterly growth to Q2 $94M $91M

  8. Slide 8: Galafold Global Commercial Momentum (as of June 30, 2023)

    Galafold Global Commercial Momentum (as of June 30, 2023) Strong patient demand and performance against key metrics lay the foundation for continued double-digit growth in 2023 Sustained Growth in 2023 Driven by: Continued penetration into existing markets Further uptake in diagnosed untreated popul

  9. Slide 9: Pombiliti + Opfolda

    Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) Potential to establish a new standard of care for people living with Pompe disease 9

  10. Slide 10: Late-Onset Pompe Disease (LOPD) Overview

    Late-Onset Pompe Disease (LOPD) Overview Late-onset Pompe disease is a rare, debilitating, and life-threatening lysosomal disorder caused by a deficiency of the enzyme acid alpha-glucosidase (GAA) Majority of patients on current ~5,000-10,000 people diagnosed Diagnosed at different stages of life, R

  11. Slide 11: Global Regulatory Status

    Global Regulatory Status Expect regulatory approvals and launch into the three largest Pompe markets in 2023  Pombiliti® + Opfolda® now approved in the EU  U.S. FDA approval expected 3Q 2023  U.K. MAA submitted via recognition procedure based on CHMP opinion  MHRA approval expected 3Q 2023 11 1D

  12. Slide 12: Ongoing Clinical Studies and Expanded Access Mechanisms

    Ongoing Clinical Studies and Expanded Access Mechanisms Advancing science though ongoing clinical studies and providing expanded access through multiple mechanisms  Ongoing clinical studies in children and adolescents1 with LOPD and infantile-onset Pompe disease (IOPD)  Multiple expanded access me

  13. Slide 13: Pombiliti + Opfolda EU Opportunity

    Pombiliti + Opfolda EU Opportunity EU Pompe market currently represents a sizeable market opportunity of $450M+  Strong indication statement: – Pombiliti® (cipaglucosidase alfa) is a long-term enzyme replacement therapy used in combination with the enzyme stabiliser Opfolda® (miglustat) for the tre

  14. Slide 14: Launch of Pombiliti + Opfolda Underway in the EU

    Launch of Pombiliti + Opfolda Underway in the EU Experienced and passionate rare disease commercial and medical organization supporting early days of launch Performance KOL and Patient Access and Outreach Reimbursement Patient Demand Promotion and Education Positive Interactions Efforts with Payors

  15. Slide 15: Corporate Outlook

    Corporate Outlook Delivering on our mission for patients and shareholders 15

  16. Slide 16: 2Q 2023 Select Financial Results

    2Q 2023 Select Financial Results 2Q23 revenue of $94.5M and growth rate of 17% at CER (in thousands, except per share data) Jun. 30, 2023 Jun. 30, 2022 Product Revenue $94,503 $80,731 Cost of Goods Sold 9,114 8,197 R&D Expense 35,149 78,319 SG&A Expense 65,423 53,379 Changes in Fair Value of Conting

  17. Slide 17: Financial Outlook and Path to Profitability

    Financial Outlook and Path to Profitability Clear strategy to build our business, advance our portfolio, and achieve profitability Sustain Revenue Secure Approvals Deliver on Growth of AT-GAA Financial Goals $180.8M 1H 2023 revenue, Focused on prudent +16% YoY expense management Galafold and operati

  18. Slide 18: Positioned for Significant Value Growth

    Positioned for Significant Value Growth Focused on execution and driving sustainable double-digit revenue growth on path to profitability Continue to Successful Advance Fully leverage Achieve bring Galafold® launch of AT- next-generation global non-GAAP to as many GAA for people gene therapies in ca

  19. Slide 19: Appendix

    Appendix

  20. Slide 20: Appendix: Reconciliation of Non-GAAP Financial Measures

    Appendix Amicus Therapeutics, Inc. Reconciliation of Non-GAAP Financial Measures (in thousands) Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Total operating expenses - as reported GAAP $104,249 $133,147 $221,213 $279,619 Research and development: Stock-based compensation

  21. Slide 21: 2022 Environmental, Social, & Governance (ESG) Snapshot

    2022 Environmental, Social, & Governance (ESG) Snapshot Who We Serve Environmental Our mission is to Diversity, Equity, & Management drive sustainability with our partners Inclusion (DEI) Address a rare genetic disease by incorporating Programs we Committed to producing Pledge to support a more incl

  22. Slide 22: FX Sensitivity and Galafold Distribution of Quarterly Sales

    FX Sensitivity and Galafold Distribution of Quarterly Sales Impact from Foreign Currency Q2 2023 Currency Variances: Q2 2022 Q2 2023 YoY Variance USD/ EUR 1.066 1.089 2.2% Distribution of Galafold Revenue GBP by Quarter in Past 5 years: 1.257 1.251 (0.5%) JPY 0.008 0.007 (5.6%) Q1 Q2 Q3 Q4 5 Year Av

  23. Slide 23: Amicus Pipeline

    Amicus Pipeline Streamlined rare disease pipeline with focus on Fabry disease and Pompe disease franchises INDICATION D I S C O V E R Y P R E C L I N I C A L P H A S E 1 / 2 P H A S E 3 R E G U L A T O R Y C O M M E R C I A L FA B RY F R A N C H I S E Galafold® ODD (migalastat) Fabry Gene Therapy Ne

  24. Slide 24: Thank you

    Thank you

Amicus Therapeutics — Q2 2023 Earnings Presentation on 6ix